News & Updates
Filter by Specialty:
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023
NAFLD a risk factor for young-onset hypertension
Young people with nonalcoholic fatty liver disease (NAFLD) are at increased risk of hypertension, especially women and those with more severe hepatic steatosis, as shown in a study.
NAFLD a risk factor for young-onset hypertension
09 Jun 2023
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
25 May 2023
SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB
The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk of incident hepatocellular carcinoma (HCC) in patients with coexisting type 2 diabetes mellitus (T2DM) and chronic hepatitis B (CHB), a territory-wide cohort study in Hong Kong has shown.
